The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors

The phosphoinositide-3 (OH) kinase (PI3K) signaling cascade is involved in regulating glucose uptake and metabolism, growth, motility, and other essential functions for cell survival. Unregulated activation of this pathway commonly occurs in cancer through a variety of mechanisms, including genetic mutations of kinases and regulatory proteins, epigenetic alterations that alter gene expression and translation, and posttranslational modifications. In thyroid cancer, constitutive activation of PI3K signaling has been shown to play a role in the genetic predisposition for thyroid neoplasia in Cowden's syndrome, and is recognized to be frequently overactivated in sporadic forms of thyroid cancer including those with aggressive clinical behaviors. In this review, the key signaling molecules in the PI3K signaling cascade, the abnormalities known to occur in thyroid cancer, and the potential for therapeutic targeting of PI3K pathway members will be discussed.

[1]  W. Scherbaum,et al.  Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[2]  E. Van Obberghen,et al.  Effect of Phosphoinositide-Dependent Kinase 1 on Protein Kinase B Translocation and Its Subsequent Activation , 2000, Molecular and Cellular Biology.

[3]  R. Roth,et al.  Akt, a Pleckstrin Homology Domain Containing Kinase, Is Activated Primarily by Phosphorylation* , 1996, The Journal of Biological Chemistry.

[4]  Gaetano Rocco,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung , 2008, Cell cycle.

[5]  J A Bond,et al.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. , 1998, The American journal of pathology.

[6]  M. Birnbaum,et al.  Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration* , 2006, Journal of Biological Chemistry.

[7]  Se Hoon Kim,et al.  Expression of down stream molecules of RET (p-ERK, p-p38 MAPK, p-JNK and p-AKT) in papillary thyroid carcinomas. , 2004, Yonsei medical journal.

[8]  M. Willingham,et al.  Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. de Leiva,et al.  PTEN promoter methylation in sporadic thyroid carcinomas. , 2006, Thyroid : official journal of the American Thyroid Association.

[10]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[11]  Xiang-Xi Xu,et al.  Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. , 2008, Cancer research.

[12]  Marc Montminy,et al.  TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver , 2003, Science.

[13]  J. Jen,et al.  Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors , 1998, Genes, chromosomes & cancer.

[14]  A. Toker,et al.  3'-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. , 2002, Frontiers in bioscience : a journal and virtual library.

[15]  A. El‐Naggar,et al.  Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.

[16]  K. Takano,et al.  Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. , 2003, Endocrine journal.

[17]  E. Henske,et al.  Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease , 2005, Oncogene.

[18]  Sheue-yann Cheng,et al.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Yang,et al.  Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation , 2009, PloS one.

[20]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[22]  J. Sagartz,et al.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.

[23]  G. Mills,et al.  A novel AKT3 mutation in melanoma tumours and cell lines , 2008, British Journal of Cancer.

[24]  A. Toker,et al.  Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.

[25]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[26]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[27]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[28]  G. Mills,et al.  Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. , 2009, Cancer research.

[29]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[30]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[31]  M. Andjelkovic,et al.  Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Eng,et al.  The nuclear affairs of PTEN , 2008, Journal of Cell Science.

[33]  V. Vasko,et al.  Akt1 contains a functional leucine-rich nuclear export sequence. , 2005, Biochemical and biophysical research communications.

[34]  B. Caillou,et al.  Detection of activated ras oncogenes in human thyroid carcinomas. , 1988, Oncogene.

[35]  B. Hemmings,et al.  Advances in protein kinase B signalling: AKTion on multiple fronts. , 2004, Trends in biochemical sciences.

[36]  M. Santoro,et al.  RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. , 2006, European journal of endocrinology.

[37]  G. Chiappetta,et al.  RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. , 2001, European journal of endocrinology.

[38]  J. Stock,et al.  Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.

[39]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[40]  J. Testa,et al.  AKT signaling in normal and malignant cells , 2005, Oncogene.

[41]  P. Vogt,et al.  Oncogenic signaling of class I PI3K isoforms , 2008, Oncogene.

[42]  P. Ladenson,et al.  Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[43]  F. Wyllie,et al.  Activated ras oncogenes in human thyroid cancers. , 1988, Cancer research.

[44]  G. Z. Cheng,et al.  Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.

[45]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[46]  R. Weigel,et al.  Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. , 1999, Biochemical and biophysical research communications.

[47]  A. Newton,et al.  Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site* , 2000, The Journal of Biological Chemistry.

[48]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[49]  Caroline Kim,et al.  AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. , 2005, Endocrinology.

[50]  H. Koh,et al.  Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  P. Edwards,et al.  Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism , 1999, Oncogene.

[52]  B. Evers,et al.  Activation of PPARγ increases PTEN expression in pancreatic cancer cells , 2003 .

[53]  D. Powell,et al.  The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. , 1998, Cancer research.

[54]  J. Dumont,et al.  Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. , 2000, The Biochemical journal.

[55]  H. Northrup,et al.  Tuberous sclerosis complex: disease modifiers and treatments. , 2008, Current opinion in pediatrics.

[56]  N. Eberhardt,et al.  The Paired Box-8/Peroxisome Proliferator-Activated Receptor-γ Oncogene in Thyroid Tumorigenesis , 2007 .

[57]  B. Hemmings,et al.  Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[59]  M. Willingham,et al.  Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. , 2002, Thyroid : official journal of the American Thyroid Association.

[60]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[61]  B. Weintraub,et al.  Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency. , 1993, The Journal of clinical investigation.

[62]  P. Vogt,et al.  Cancer-specific mutations in phosphatidylinositol 3-kinase. , 2007, Trends in biochemical sciences.

[63]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[64]  Y. Pekarsky,et al.  The role of TCL1 in human T-cell leukemia , 2001, Oncogene.

[65]  E. Fridman,et al.  AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma. , 2009, Cancer genetics and cytogenetics.

[66]  M. Saji,et al.  Overexpression and overactivation of Akt in thyroid carcinoma. , 2001, Cancer research.

[67]  M. Santoro,et al.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.

[68]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[69]  L. Bastholt,et al.  Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.

[70]  M. Benezra,et al.  BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. , 2008, The Journal of clinical endocrinology and metabolism.

[71]  B. Evers,et al.  Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. , 2007, Journal of the American College of Surgeons.

[72]  M. Willingham,et al.  Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. , 2007, Carcinogenesis.

[73]  G. Chiappetta,et al.  RET activation and clinicopathologic features in poorly differentiated thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[74]  M. Willingham,et al.  PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer , 2009, Oncogene.

[75]  T. Giordano,et al.  Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. , 2009, Endocrinology.

[76]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[77]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[78]  R. Abraham,et al.  The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy , 2007, Clinical Cancer Research.

[79]  M. McMahon,et al.  Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[80]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[81]  Peter Kraft,et al.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Yuri E Nikiforov,et al.  Thyroid carcinoma: molecular pathways and therapeutic targets , 2008, Modern Pathology.

[83]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[84]  T. Haruta,et al.  Mammalian Target of Rapamycin Pathway Regulates Insulin Signaling via Subcellular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of Insulin , 2001, Molecular and Cellular Biology.

[85]  Y. Gotoh,et al.  Scaffolding function of PAK in the PDK1–Akt pathway , 2008, Nature Cell Biology.

[86]  Wei Wang,et al.  High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[87]  A. Di Cristofano,et al.  Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. , 2007, Cancer research.

[88]  G. Chiappetta,et al.  Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. , 1996, Oncogene.

[89]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[90]  M. Saji,et al.  Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. , 2001, Thyroid : official journal of the American Thyroid Association.

[91]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[92]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[93]  Hong Liu,et al.  Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[95]  D. Stokoe The phosphoinositide 3-kinase pathway and cancer , 2005, Expert Reviews in Molecular Medicine.

[96]  P. Hou,et al.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. , 2008, The Journal of clinical endocrinology and metabolism.

[97]  T. Roberts,et al.  Should individual PI3 kinase isoforms be targeted in cancer? , 2009, Current opinion in cell biology.

[98]  A. Grossman,et al.  Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. , 2008, Endocrine-related cancer.

[99]  B. Park,et al.  Knockin of mutant PIK3CA activates multiple oncogenic pathways , 2009, Proceedings of the National Academy of Sciences.

[100]  Robert D Cardiff,et al.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.

[101]  J. Gutkind,et al.  A Novel Role for Phosphatidylinositol 3-Kinase β in Signaling from G Protein-coupled Receptors to Akt* , 2000, The Journal of Biological Chemistry.

[102]  G. Viglietto,et al.  PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 , 2000, Oncogene.

[103]  A. Bilancio,et al.  Signalling by PI3K isoforms: insights from gene-targeted mice. , 2005, Trends in biochemical sciences.

[104]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[105]  J. Yeh,et al.  Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. , 2000, The American journal of pathology.

[106]  M. Pierotti,et al.  TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. , 1992, Oncogene.

[107]  M. Santoro,et al.  Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. , 2003, Molecular endocrinology.

[108]  P. Cohen,et al.  Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.

[109]  A. El‐Naggar,et al.  Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[110]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Huiling He,et al.  Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion , 2007, Proceedings of the National Academy of Sciences.

[112]  A. Di Cristofano,et al.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. , 2009, Cancer research.

[113]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[114]  B. Hemmings,et al.  Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.

[115]  P. Vogt,et al.  Oncogenic transformation induced by membrane-targeted Akt2 and Akt3 , 2001, Oncogene.

[116]  S. Sherman Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. , 2009, The Journal of clinical endocrinology and metabolism.

[117]  Carmen Blanco-Aparicio,et al.  PTEN, more than the AKT pathway. , 2007, Carcinogenesis.

[118]  M. Ringel,et al.  Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. , 2008, Endocrinology and metabolism clinics of North America.

[119]  V. Vasko,et al.  Chronic expression of RET/PTC 3 enhances basal and insulin‐stimulated PI3 kinase/AKT signaling and increases IRS‐2 expression in FRTL‐5 thyroid cells , 2004, Molecular carcinogenesis.

[120]  Hong Wang,et al.  Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. , 2006, Cancer research.

[121]  G. Viglietto,et al.  Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. , 2005, The American journal of pathology.

[122]  S. Staal Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[123]  Brian A. Hemmings,et al.  Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding , 2006, Molecular and Cellular Biology.

[124]  W. Liu,et al.  Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.

[125]  Brian A. Hemmings,et al.  Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane , 2001, Science.

[126]  D. Rawlings,et al.  Protein Kinase C βII Regulates Akt Phosphorylation on Ser-473 in a Cell Type- and Stimulus-specific Fashion*♦ , 2004, Journal of Biological Chemistry.

[127]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[128]  Satoshi Matsumoto,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[129]  J. Wesselink,et al.  Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. , 1999, European journal of biochemistry.

[130]  M. Sughayer,et al.  The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias , 2008, British Journal of Cancer.

[131]  P. Hou,et al.  Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3‐kinase/AKT signaling pathway in thyroid tumors , 2008, Cancer.

[132]  Erica A Golemis,et al.  Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2 , 1999, Oncogene.

[133]  M. Saji,et al.  AKT in thyroid tumorigenesis and progression. , 2007, Endocrinology.

[134]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[135]  Michael C. Ostrowski,et al.  Genomic alterations in tumor stroma. , 2009, Cancer research.

[136]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[137]  J. Meinkoth,et al.  Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation , 2000, Oncogene.

[138]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[139]  M. Ladanyi,et al.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.

[140]  Pier Paolo Pandolfi,et al.  The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.

[141]  N. Masuyama,et al.  Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells , 2001, Current Biology.

[142]  P. Vogt,et al.  Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[143]  M. Pierotti,et al.  Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium , 1995, Journal of endocrinological investigation.

[144]  B. Nelkin,et al.  Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[145]  J. Qin,et al.  SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.

[146]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  Charis Eng,et al.  Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer , 2002, Genes, chromosomes & cancer.

[148]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[149]  A. Toker,et al.  Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. , 2009, Cellular signalling.

[150]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[151]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[152]  V. Vasko,et al.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer , 2004, Journal of Medical Genetics.

[153]  David Sidransky,et al.  Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. , 2007, The Journal of clinical endocrinology and metabolism.

[154]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[155]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[156]  Metin N. Gurcan,et al.  Pten in Stromal Fibroblasts Suppresses Mammary Epithelial Tumors , 2009, Nature.

[157]  C. Larsson,et al.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.

[158]  H. Koh,et al.  Inhibition of Akt and Its Anti-apoptotic Activities by Tumor Necrosis Factor-induced Protein Kinase C-related Kinase 2 (PRK2) Cleavage* , 2000, The Journal of Biological Chemistry.

[159]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.